... the Department of Justice to open an investigation into Danco Laboratories, the manufacturer of the dangerous chemical abortion drug....

... that the Department fulfill its mandate by investigating Danco’s original FDA approval, ongoing regulatory compliance, manufacture and distribution pipeline, potentially deceptive marketing practices, and disclosure of safety risks pertaining to the company’s sole product—the chemical abortion drug, mifepristone. 

Danco is profiting at the expense of women who have taken the drug and been seriously harmed by it. The largest study of mifepristone ever conducted found that nearly 11% of women who take the drug experience a “serious adverse health event,” such as sepsis or hemorrhaging. That rate amounts to 22 times higher than what Danco admits to on its label.

... tasked with upholding the rule of law and protecting every American—including women that companies like Danco prey on and lie to. This mandate includes ensuring Danco’s prompt, fulsome, and transparent compliance with all applicable laws, regulations, and ongoing regulatory obligations.

The company first introduced mifepristone in the United States in 2000 and, in doing so, appears to have taken unusual and extreme measures to protect itself from liability.

It was incorporated in the Cayman Islands. Its board of directors and investors remain secret. And its corporate structure remains largely shielded from public view.

Early backers appear to have included George Soros and other far-left activists who favor population control.

We do know... that chemical abortion is a lucrative enterprise for Danco—so lucrative, in fact, that mifepristone is the only drug the company makes, with investors’ returns reportedly topping 450%.

Initially, the original manufacturer of the abortion-inducing drug was obscured by secrecy...for decades, even the location of Danco's manufacturing facility remained undisclosed.

...Following the refusal of established pharmaceutical companies to market the abortion-inducing drug in the United States, a consortium established a "secret company" exclusively dedicated to its production and commerce, according to The Seattle Times.

This protracted 11-year undertaking involved what The Seattle Times called an elaborate "cloak-and-dagger scheme” to hide the identities of participants, numerous legal disputes, and $50 million in incurred costs...

...In the years that followed, the manufacturing location remained confidential until a False Claims Act settlement against Danco in the spring of 2025 mandated the company to publicly indicate the country of origin on its packaging. Danco's current packaging now lists Spain as the country of origin.

President Trump’s record on protecting unborn life and defending women’s health is unmatched. The Department of Justice will continue to advance those priorities by asking courts to allow the FDA to complete its review of mifepristone safety data and by investigating any person or entity that engaged in illegal conduct putting women or unborn children at risk.

... the Department of Justice to open an investigation into Danco Laboratories, the manufacturer of the dangerous chemical abortion drug....

... that the Department fulfill its mandate by investigating Danco’s original FDA approval, ongoing regulatory compliance, manufacture and distribution pipeline, potentially deceptive marketing practices, and disclosure of safety risks pertaining to the company’s sole product—the chemical abortion drug, mifepristone. 

Danco is profiting at the expense of women who have taken the drug and been seriously harmed by it. The largest study of mifepristone ever conducted found that nearly 11% of women who take the drug experience a “serious adverse health event,” such as sepsis or hemorrhaging. That rate amounts to 22 times higher than what Danco admits to on its label.

... tasked with upholding the rule of law and protecting every American—including women that companies like Danco prey on and lie to. This mandate includes ensuring Danco’s prompt, fulsome, and transparent compliance with all applicable laws, regulations, and ongoing regulatory obligations.

The company first introduced mifepristone in the United States in 2000 and, in doing so, appears to have taken unusual and extreme measures to protect itself from liability.

It was incorporated in the Cayman Islands. Its board of directors and investors remain secret. And its corporate structure remains largely shielded from public view.

Early backers appear to have included George Soros and other far-left activists who favor population control.

We do know... that chemical abortion is a lucrative enterprise for Danco—so lucrative, in fact, that mifepristone is the only drug the company makes, with investors’ returns reportedly topping 450%.

Initially, the original manufacturer of the abortion-inducing drug was obscured by secrecy...for decades, even the location of Danco's manufacturing facility remained undisclosed.

...Following the refusal of established pharmaceutical companies to market the abortion-inducing drug in the United States, a consortium established a "secret company" exclusively dedicated to its production and commerce, according to The Seattle Times.

This protracted 11-year undertaking involved what The Seattle Times called an elaborate "cloak-and-dagger scheme” to hide the identities of participants, numerous legal disputes, and $50 million in incurred costs...

...In the years that followed, the manufacturing location remained confidential until a False Claims Act settlement against Danco in the spring of 2025 mandated the company to publicly indicate the country of origin on its packaging. Danco's current packaging now lists Spain as the country of origin.

President Trump’s record on protecting unborn life and defending women’s health is unmatched. The Department of Justice will continue to advance those priorities by asking courts to allow the FDA to complete its review of mifepristone safety data and by investigating any person or entity that engaged in illegal conduct putting women or unborn children at risk.